Study identifier:NIS-CME-CRE-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficiency of rosuvastatin versus the fixed combination of Ezetimibe/Simvastatin to reduce the cholesterol levels in outpatients in a realistic environment. A Retrospective Study
Dyslipidemia
-
No
-
All
268
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim of this study is to evaluate the effectiveness of Rosuvastatin versus Ezetimibe/Simvastatin in dyslipidemic patients treated for at least 8 weeks.
Location
Location
Durango, Mexico
Location
Mexico, DF, Mexico
Location
Guadalajara, Jalisco, Mexico
Location
Cuernavaca, Morelos, Mexico
Location
Monterrey, Nuevo Leon, Mexico
Location
Puebla, PUEBLA, Mexico
Location
San Luis Potosi, San Luis Potosi, Mexico
Location
Veracruz, Xalapa, Mexico
Arms | Assigned Interventions |
---|---|
Dislipidemic Population People with high levels of total cholesterol, LDL, C-HDL and triglycerides | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.